Novo Nordisk has announced that a phase 3 clinical trial of its diabetes drug, Ryzodeg, showed improved control of blood sugar levels compared to biphasic insulin aspart 30 (NovoMix® 30).
Ryzodeg is the first combination of two distinct insulin analogues, Tresiba (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes.
Lead investigator Gregory Fulcher, Royal North Shore Hospital, Sydney, Australia.
Data presented at the World Diabetes Congress of the International Diabetes Federation (IDF) showed that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period with Ryzodeg compared to biphasic insulin as part 30, both administered twice-daily.
Ryzodeg has been approved in Japan, Mexico, EU, Norway, Iceland, Switzerland, El Salvador and Chile.